E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
homozygous familial hypercholesterolemia |
|
E.1.1.1 | Medical condition in easily understood language |
genetic defect for high cholesterol in blood |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020604 |
E.1.2 | Term | Hypercholesterolemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of the base treatment phase is to assess the impact of 12 intravenous infusions of 8 mg/kg CER-001 given at 2-week intervals (i.e., every 10 to 18 days) on descending thoracic aorta and carotid wall area and volume using 3T magnetic resonance imaging (3TMRI), when administered to patients with genetically-confirmed homozygous familial hypercholesterolemia (HoFH). The objective of the extension phase is to assess the additional benefit as well as the safety of continued use of CER-001 for a one year period (24 total infusions). |
|
E.2.2 | Secondary objectives of the trial |
Base treatment phase:
•Assess 6M efficacy data to determine continuation of ext.phase
•% change in carotid vessel wall vol.
•Abs. change carotid vessel wall vol.
•%change the mean of the carotid normalized wall index
•%change maximum vessel wall thickness
•%change mean vessel wall thickness
•%change thoracic aorta vessel wall vol.measured by 3TMRI
•%change thoracic aorta mean vessel wall area
•Abs.change thoracic aorta vessel wall vol.
•%change carotid lipid core vol.
•Abs.change carotid lipid core vol.
•%change carotid calcified vessel wall vol.
•Abs. change carotid calcified vessel wall vol.
•%change carotid intra-plaque hemorrhage vol.
•Abs. change carotid intra-plaque hemorrhage vol.
Ext. phase:
•%change baseline to 12M carotid mean vessel wall area measured by 3TMRI
•%change 6M to12M carotid mean vessel wall area measured by 3TMRI
•Overall %change baseline to 12M carotid mean vessel wall area measured by 3TMRI
•Continued safety monitoring --> study duration |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male or female subjects 12 year or older with homozygous FH (confirmed by genetic testing)
Subject or subject guardian must sign informed consent (pediatric subject must sign assent if applciable)
Subject must be willing to participate and comply with all protocol requirements.
Subject must be enrolled in MODE before 31Dec2012 to be eligible to participate in safety extension phase
|
|
E.4 | Principal exclusion criteria |
Subjects weighing more than 100 kg at screening.
Subjects with significant health problems in the recent past including blood disorders, cancer or digestive problems.
Females who are pregnant, breastfeeding, or plan to become pregnant during the study.
Subject has known major hematologic, reanl, hepatic, metabolic, GI or endocrine dysfunction. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint in this study is the percent change from baseline to follow-up in carotid mean vessel wall area as measured by 3TMRI. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline and 1-3 weeks after last infusion:
6m (1-3 weeks after infusion 12)
12m (1-3 weeks after infusion 24) |
|
E.5.2 | Secondary end point(s) |
Secondary outcome measurements for the base treatment phase will include:
• Assessment of six month efficacy data for determination of continuation of extension
phase
• Percent change in carotid vessel wall volume
• Absolute change in carotid vessel wall volume
• Percent change in the mean of the carotid normalized wall index
• Percent change in maximum vessel wall thickness
• Percent change in mean vessel wall thickness
• Percent change in thoracic aorta vessel wall volume as measured by 3TMRI
• Percent change in thoracic aorta mean vessel wall area
• Absolute change in thoracic aorta vessel wall volume
• Percent change in carotid lipid core volume
• Absolute change in carotid lipid core volume
• Percentage change in carotid calcified vessel wall volume
• Absolute change in carotid calcified vessel wall volume
• Percent change in carotid intra-plaque hemorrhage volume
• Absolute change in carotid intra-plaque hemorrhage volume
Secondary efficacy neasurements for the extension phase will include:
• Percent change from baseline to twelve months in carotid mean vessel wall area as
measured by 3TMRI
• Percent change from six months to twelve months in carotid mean vessel wall area as
measured by 3TMRI
• Overall percent change from baseline to twelve months carotid mean vessel wall area
as measured by 3TMRI
• Continued safety monitoring throughout the study duration |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline and 1-3 weeks after last infusion:
6m (1-3 weeks after infusion 12)
12m (1-3 weeks after infusion 24) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
France |
Italy |
Netherlands |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |